Physician profile
Daniel Nadeau
NPI 1215902226
$1,162,739.09
in general payments reported to CMS, 2019-2025
37 companies · $146K in 2025
The $146K reported for 2025 was more than what 99% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $237K · 2020: $150K · 2021: $193K · 2022: $174K · 2023: $140K · 2024: $122K · 2025: $146K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $358K · Travel and Lodging: $16K · Food and Beverage: $15K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $13K · Consulting Fee: $6,186 · Education: $89.53.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $358,426.94 |
| Travel and Lodging | $15,650.32 |
| Food and Beverage | $15,402.11 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $12,639.00 |
| Consulting Fee | $6,185.50 |
| Education | $89.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $658,563.94 | 2019-2025 | Mounjaro, Jardiance, Trulicity |
| Novo Nordisk INC | $324,568.75 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $94,891.37 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals Lp | $38,922.99 | 2019-2023 | Farxiga |
| Dexcom, INC. | $15,409.43 | 2019-2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor, Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $9,907.37 | 2021-2024 | |
| Cequr Corporation | $8,872.88 | 2022-2024 | Cequr Simplicity |
| Insulet Corporation | $3,731.85 | 2019-2025 | Omnipod |
| Alexion Pharmaceuticals, INC. | $1,526.15 | 2019-2024 | Strensiq |
| Mannkind Corporation | $1,322.24 | 2019-2024 | |
| Amgen INC. | $897.57 | 2019-2025 | Repatha, Repatha, Tepezza |
| Radius Health, INC. | $517.38 | 2020-2025 | Tymlos |
| Corcept Therapeutics | $438.89 | 2019-2024 | Korlym |
| Tandem Diabetes Care, INC. | $400.50 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Abbott Laboratories | $366.43 | 2019-2025 | Freestyle Libre 3 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $308.34 | 2019-2024 | |
| Sequel Med Tech, LLC | $281.19 | 2025 | Twiist |
| Abbvie INC. | $264.02 | 2019-2025 | |
| Medtronic, INC. | $240.06 | 2022-2025 | Signia, Minimed 780g, Intellis Adaptivestim |
| Janssen Pharmaceuticals, INC | $155.30 | 2019 | |
| Kyowa Kirin, INC. | $119.72 | 2023-2025 | Crysvita |
| Lexicon Pharmaceuticals, INC. | $119.49 | 2024 | Inpefa |
| Intra-Sana Laboratories | $119.45 | 2024-2025 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Horizon Therapeutics Plc | $117.72 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $116.82 | 2019 | |
| Alvogen INC | $98.12 | 2022-2025 | Teriparatide |
| Ibsa Pharma INC. | $89.91 | 2019-2020 | |
| Amarin Pharma, INC. | $86.73 | 2020 | |
| Beta Bionics, INC. | $63.19 | 2024 | Ilet Bionic Pancreas |
| Novartis Pharmaceuticals Corporation | $58.86 | 2022-2025 | |
| Antares Pharma, INC. | $46.01 | 2019 | |
| Xeris Pharmaceuticals, INC. | $36.39 | 2022-2025 | Gvoke Hypopen |
| Madrigal Pharmaceuticals | $18.81 | 2025 | Rezdiffra |
| Amneal Pharmaceuticals LLC | $16.69 | 2019 | |
| Lifescan, INC. | $16.01 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $15.61 | 2021 | |
| Sun Pharmaceutical Industries INC. | $12.91 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Nadeau listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.